An innovative private equity firm utilizing a virtual pharma (asset centric) model is looking to in-license early stage pharmaceutical assets, and is capable of providing $15-$20 million, or more, to get a project through proof of concept. The firm prefers to in-license or acquire individual pharmaceutical assets and is much less likely to make traditional equity investments into companies. Ideal candidates have yet to receive significant VC funding and the firm prefers to invest without syndicates. The firm integrates the founders and their company into a special purpose vehicle and works with them in a very close collaborative way to maximize the product value. The firm is interested in investing in projects around the globe and is capable of making 10+ investments over the course of the next year if enough high quality investments present themselves.

The firm is looking primarily for pharmaceutical assets and to a much lesser extent diagnostics and medical devices. The firm is willing to invest in assets that are as far as 12-18 months pre-IND to those that are early in phase I of clinical trials and ideal candidates are IND ready and preparing to enter phase I. The firm is open to all therapeutic areas and indications where proof of concept can be shown in early clinical trials. For medical device and diagnostic opportunities only very select programs of extreme appeal will be considered.

The firm is looking to partner with management teams that have an extreme understanding of the science behind their product that are willing to operate in a virtual environment. The firm acts as an extremely hands on investor often integrating investments into the parent company and ensuring that all assets are developed in the most effective manner with high focus on early development de-risking.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An institutional alternative investor based in France manages an internal division dedicated exclusively to direct investments in the life sciences. The firm is currently investing out of its 4th fund which recently closed at $250 million bringing its total assets under management to over $1 billion. The firm invests anywhere from $2 to $20 million into its portfolio companies and is capable of investing into approximately 10 companies from its 4th fund. The firm looks to act as the lead investor into companies providing equity capital and assuming approximately a 20% shareholding. The firm is looking to invest primarily in companies based in Europe but has 20% of its portfolio dedicated to global investments.

The firm is looking for companies developing Therapeutics, Medical Devices and Molecular Diagnostics. The firm is open to the spectrum of subsectors and indications; however it is reluctant to allocate to cell or gene therapy and has significant experience in diabetes so companies targeting this indication are of special interest. The firm also is willing to consider companies targeting orphan indications. For therapeutics companies the firm is looking for opportunities in early Phase I or later. For medical devices the company must have some in human data to be considered.

The firm looks to have strong involvement in the firm’s management team and hold positions on the company’s Board. The firm looks to hold investments for 2-6 years before selling shares, generally to a large company that will finalize the products commercialization. Companies located outside of Europe are often recommended and advised by the firm on opening up subsidiaries in Europe using the firm’s vast European network

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital company founded in 1996 with offices in the US and Europe is currently making investments out of its vintage 2012 $200 million life science focused fund. The fund is backed 50% by two large pharma companies who are members of the fund’s scientific advisory board. The firm’s investment size is variable although they look to invest in companies who are able to reach a substantial value inflection point and exit with $15-$20 million in total investment over 4-6 years. The firm is looking for companies located around the globe. The firm is actively seeking new investment opportunities.

The firm is currently seeking to invest in companies developing therapeutics. The firm is generally agnostics across indication areas and technology types and is open to reviewing small molecules and biologics as well as cell and gene therapy. The firm is looking for companies with a lead asset anywhere from the Pre-clinical phase to Phase II of clinical trials. The firm’s main investment strategy is to back/create virtual companies focused around a single therapeutic asset. The firm is able to invest in particularly early stages of companies working with antibodies and biologics as they have significant domain expertise in these areas. For companies working with novel mechanisms of action the firm requires there be a strong understanding of the underlying sciences, and for companies working with pre-existing pathways or technologies there must be clear evidence of differentiation.

The firm is looking for companies where the founders have some involvement, either in management or as advisors/consultants to ensure the project as the scientific support required to succeed. The firm looks to play an active role in companies and takes a board seat following investment. The firm is willing to invest in both private and publically held companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm that was founded in 2011 and is based in China is managing one fund with committed capital of $140million. The firm typically makes equity investment into life science companies at various stages. The investment size generally ranges from $10 million to $15 million over the life of an investment.  The firm seeks to make 3-5 allocations in the next year. The firm focuses on companies that are based in the China and the US.

The firm is currently looking for new investment opportunities in Biotechnology R&D, Therapeutics & Diagnostics, Pharmaceuticals, Medical Devices and Healthcare IT spaces. The firm is very opportunistic in terms of subsectors and indications. The firm is interested in in-licensing products or technologies for development from companies outside of China, such as US-based companies. The firm also seeks to invest in orphan drugs. Prior investments have included medical device companies, diagnostics companies, CRO and distributors. The firm will consider companies in all stages, depending on the opportunity.

The firm seeks to invest in both private and public companies. The firm has no specific requirements for companies’ management team, revenue or EBITDA.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture arm of a large pharmaceutical company is mandated to invest directly in private early-stage life science companies with promising new products that may be future pipeline candidates. The firm seeks to invest across the more expansive business footprint of its parent company. The firm has a global mandate and is currently seeking new equity investment opportunities.

The firm is particularly interested in therapies for rare diseases, oncology, vaccines, and immune mediated diseases. The firm will also invest in breakthrough product candidates in other therapeutic areas such as cardiovascular and diabetes. The firm seeks products that are in preclinical or early clinical development and that have proof-of-concept data. The firm is also willing to consider medical devices targeting these indication

The firm generally co-invests with top tier life science investors and looks to take a minority position (<20%) in each portfolio company. The firm seeks to be a long-term investor with board responsibilities either as a full seat or as an observer.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private equity fund that was established in 1999 and based in New York, NY, with satellite offices in Princeton, NJ, Cambridge, MA and Brussels, Belgium is currently seeking to make investment in the life science space. The firm controls up to $1.75 billion in assets under management and makes equity investments ranging from $100,000 for academic spin-offs to $150 million in later stage deals. The firm seeks to make investments around the globe with a focus on creating and building companies located within the US and Europe.

The firm is currently looking for companies in the Therapeutics space. For therapeutics the firm is most interested in companies developing novel biologics however companies developing small molecules or biologic substitutes are also considered for investment. The firm is willing to invest in companies with a product anywhere from pre-clinical to phase III of development although they do require a substantial equity position into selected companies. For companies with an asset that is preclinical the firm tends to not get involved if the round is series C or later. The firm is not interested in later stage companies working with primary care technologies.

The firm considers both private and crossover investments and strongly prefers, if not requires to take a board seat into portfolio companies. The firm also prefers to lead or co-lead any investment syndicates and looks to optimize the asset with additional resources beyond the typical venture investment mandate. The firm also requires that the company’s management be able to clearly articulate the mechanisms and functionality of their technology.

The firm is unlike most traditional early stage investors in that they look to act as a partner, taking the company through to commercialization only selling in an M&A transaction if the price is right or access the public markets, but only if it is advantageous to do so.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture capital firm that is funded by two substantial healthcare providers makes private equity investments of strategic interest to the systems medical centers and affiliated physicians. The firm makes investment ranging anywhere from $1-$8 million over the life of the investment with the majority of allocations falling in the $5-$7 million range. The firm manages an evergreen structure and is actively looking for new opportunities throughout the United States.

The firm is currently interested in healthcare information technology, tech-enabled medical devices and tech-enabled healthcare services. For medical devices the firm is focused on tech enabled devices and is highly interested in areas of patient monitoring and wearables, among other areas. The firm is also interested in highly innovative hospital hardware and devices that have the potential to significantly lower the cost of the point of care process. The firm generally invests in companies in the series A and B rounds.

The firm is looking for companies with experienced management teams. The firm looks to act as a strategic investor generally taking a board seat. The firm is very open to syndication and general invests along with other institutional investors.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com